Want to see DCOY full AI Analyst Report?
DCOY Stock Chart & Stats
$5.81
-$0.06(-3.48%)
At close: 4:00 PM EST
$5.81
-$0.06(-3.48%)
Day’s Range― - ―
52-Week Range$4.32 - $416.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)356.88K
Market Cap
$2.68M
Enterprise Value-$4.66M
Total Cash (Recent Filing)$7.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding531,968
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-1.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Zero DebtHaving no reported debt materially reduces financial risk and preserves strategic flexibility. Over the next 2-6 months this lowers bankruptcy and interest-pressure probabilities, enabling the company to prioritize R&D spend, pursue milestone-driven financings, or partner deals rather than servicing fixed obligations.
PIPE Financing To Fund Clinical WorkA structured PIPE that provides $3.5M now and milestone-linked warrants up to $17.5M demonstrates investor willingness to fund development. This milestone-tied capital extends runway while aligning external financing with clinical progress, reducing immediate dilution and supporting multi-stage trial funding.
Advancing Lead Antiviral Toward TrialsMoving a lead antiviral toward Phase 1/Phase 2a clinical work is a structural de-risking step. Over months, clinical filings and human challenge studies shift asset value from preclinical uncertainty to data-driven valuation, increasing partner/license optionality and potential for milestone-based funding.
Bears Say
Pre-revenue With Sustained LossesOperating without revenue and generating recurring multi-million-dollar losses limits internal funding options and heightens dependency on external capital. Persisting negative results over multiple periods create execution risk, constrain strategic choices, and can force dilutive financings absent clear near-term clinical milestones.
Negative Operating And Free Cash FlowOngoing cash burn demonstrates the business is not yet self-sustaining and converts accounting losses into real liquidity depletion. Even with some TTM FCF improvement, persistent negative cash flow depletes equity, shortens runway, and necessitates continued external financing over the next several months.
Eroding Shareholders' Equity And Dilution RiskMaterial decline in equity reflects cumulative losses and signals reliance on external funding. Combined with milestone-linked warrant financings, this creates a durable dilution risk: future capital raises or warrant exercises will likely dilute holders and can constrain per-share economics even if development milestones are achieved.
Decoy Therapeutics News
DCOY FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was $4.32 and its highest was $416.05 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is $2.68M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Decoy Therapeutics has 531,968 shares outstanding.
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DCOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―